Send to

Choose Destination
Haematologica. 1996 Jul-Aug;81(4):346-8.

Achievement and maintenance of complete remission in a patient with acute myelogenous leukemia after weekly administration of interleukin-2.

Author information

Department of Hematology, Democritus University of Thrace, Alexandroupolis, Greece.


Several groups have used high doses of interleukin-2 (IL-2), achieving a significant rate of responses in patients with acute myelogenous leukemia (AML). These results have mainly been observed in AML patients with limited disease (bone marrow blasts < 25%), but this therapy is associated with significant toxicity which is dose-related. In this report we describe a patient with AML in whom conventional chemotherapy had achieved partial remission. This patient received subcutaneously intermediate doses of IL-2 (12 x 10(6)/m2/week) and achieved complete remission which was maintained for eleven months. The side effects of IL-2 were mild. The results of this report document the antileukemic effect of IL-2 in AML with limited disease as well as the efficacy of subcutaneous maintenance treatment for prolonged periods.

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center